Role of Clonal Hematopoiesis of Indeterminant Potential–Related Germline TET2 Variation in Inflammation and Cardiovascular Disease Risk: A Mendelian Randomization Study
Originally published27 Apr 2023https://doi.org/10.1161/ATVBAHA.123.319259Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43:e227–e229

Footnotes
References
- 1.
Stein A, Metzeler K, Kubasch AS, Rommel K-P, Desch S, Buettner P, Rosolowski M, Cross M, Platzbecker U, Thiele H . Clonal hematopoiesis and cardiovascular disease: deciphering interconnections.Basic Res Cardiol. 2022; 117:55. doi: 10.1007/s00395-022-00969-wCrossrefMedlineGoogle Scholar - 2.
Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D’Aco K, Fernandez A, Wache-Mainier C, . TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial.JAMA Cardiol. 2022; 7:521–528. doi: 10.1001/jamacardio.2022.0386CrossrefMedlineGoogle Scholar - 3.
Kessler MD, Damask A, O’Keeffe S, Banerjee N, Li D, Watanabe K, Marketta A, Van Meter M, Semrau S, Horowitz J, ; Regeneron Genetics Center. Common and rare variant associations with clonal hematopoiesis phenotypes.Nature. 2022; 612:301–309. doi: 10.1038/s41586-022-05448-9CrossrefMedlineGoogle Scholar - 4.
Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Günes¸ O, Hall P, Hayhurst J, . The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource.Nucleic Acids Res. 2023; 51:D977–D985. doi: 10.1093/nar/gkac1010CrossrefMedlineGoogle Scholar - 5.
Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes MV, Minelli C, Relton CL, . Guidelines for performing Mendelian randomization investigations.Wellcome Open Res. 2020; 4:186. doi: 10.12688/wellcomeopenres.15555.2CrossrefMedlineGoogle Scholar
Submit a Response to This Article